Praelia Pharmaceuticals, the commercial arm of Vestiq, will sell GelX that is scheduled to launch in the first quarter of 2013 in the US.
BMG Pharma president and CEO Marco Mastrodonato said GelX is new method of oral mucositis treatment in cancer patients.
"Providers are now able to ensure their patients receive the best care possible by using our innovative delivery technology to eliminate swallowing issues and discomfort associated with chemotherapy, radiotherapy, and related pharmacologic therapies," Mastrodonato added.
According to the GelX distribution deal, Vestiq will make an undisclosed upfront payment in addition to sales based royalty payments.
Vestiq chairman and CEO Martin Baum said, "The delivery technology associated with GelX is a significant breakthrough in the ease of use and compliance associated to patients presenting with Oral Mucositis."